RCMNY
HRTX icon

Rubric Capital Management (New York)’s Heron Therapeutics HRTX Stock Holding History

Rubric Capital Management (New York)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24M Hold
30,046,828
– – 0.25% 61
2025
Q4 		$39.1M Buy
30,046,828
+946,100
+3% +$1.17M 0.47% 50
2025
Q3 		$36.7M Buy
29,100,728
+2,387,225
+9% +$3.78M 0.41% 46
2025
Q2 		$55.3M Hold
26,713,503
– – 0.84% 33
2025
Q1 		$58.8M Hold
26,713,503
– – 1.05% 28
2024
Q4 		$40.9M Hold
26,713,503
– – 0.52% 38
2024
Q3 		$53.2M Hold
26,713,503
– – 0.87% 32
2024
Q2 		$93.5M Hold
26,713,503
– – 2.45% 11
2024
Q1 		$74M Hold
26,713,503
– – 2.19% 14
2023
Q4 		$45.4M Hold
26,713,503
– – 0.94% 25
2023
Q3 		$27.5M Buy
26,713,503
+14,963,503
+127% +$21.3M 1.03% 30
2023
Q2 		$13.6M Hold
11,750,000
– – 0.58% 41
2023
Q1 		$17.7M Hold
11,750,000
– – 0.46% 46
2022
Q4 		$29.4M Buy
11,750,000
+9,233,672
+367% +$29.7M 1.28% 26
2022
Q3 		$10.6M Buy
+2,516,328
New +$9.85M 0.53% 45
2019
Q2 		– Sell
-1,500,000
Closed -$36.7M – 62
2019
Q1 		$36.7M Sell
1,500,000
-1,287,592
-46% -$33.7M 3.42% 9
2018
Q4 		$72.3M Buy
2,787,592
+828,742
+42% +$22.8M 8.95% 1
2018
Q3 		$62M Buy
1,958,850
+818,603
+72% +$30.5M 6.55% 3
2018
Q2 		$44.3M Sell
1,140,247
-369,761
-24% -$11.8M 4.35% 10
2018
Q1 		$41.7M Sell
1,510,008
-687,304
-31% -$15.6M 3.88% 10
2017
Q4 		$39.8M Buy
2,197,312
+297,312
+16% +$4.85M 4.91% 3
2017
Q3 		$30.7M Buy
1,900,000
+200,000
+12% +$3.14M 2.78% 6
2017
Q2 		$23.5M Buy
1,700,000
+100,000
+6% +$1.45M 4.85% 2
2017
Q1 		$24M Buy
1,600,000
+1,050,000
+191% +$14.5M 6.99% 2
2016
Q4 		$7.21M Buy
+550,000
New +$8.63M 2.48% 12

Other funds holding HRTX

CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Rubric Capital Management (New York)'s HRTX Position: Q1 2026 in Review

Rubric Capital Management (New York) held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 30,046,828 shares worth $24M. The position accounts for 0.25% of the portfolio, ranked #61.

Rubric Capital Management (New York) first reported a position in HRTX in Q4 2016 and has held it in 25 quarters since. The position peaked at $93.5M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Rubric Capital Management (New York) held 30,046,828 shares of Heron Therapeutics worth $24M as of Q1 2026.
  • Rubric Capital Management (New York) left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 0.25% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #61 holding.
  • Rubric Capital Management (New York) first reported a position in Heron Therapeutics in Q4 2016 and has held it in 25 quarters since.
  • Rubric Capital Management (New York)'s Heron Therapeutics position peaked at $93.5M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.